Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

May 27, 2022

NovoMedix gets NIH grant to advance NMX1 in TNBC

The National Heart, Lung, and Blood Institute division of the NIH has awarded biotechnology company NovoMedix a $2m Phase II SBIR grant to further the development of novel small molecules that protect patients with triple-negative breast cancer (TNBC) from the long-term cardiotoxic impacts of doxorubicin chemotherapy.

NovoMedix gets NIH grant to advance NMX1 in TNBC